Logo image
Octreotide and cholecystokinin antagonist reduce edema in obstruction-induced acute pancreatitis
Journal article   Peer reviewed

Octreotide and cholecystokinin antagonist reduce edema in obstruction-induced acute pancreatitis

Y Toriumi, I Samuel, D P Wilcockson, C M Turkelson, T E Solomon and R J Joehl
The Journal of laboratory and clinical medicine, Vol.122(4), pp.450-454
10/1993
PMID: 8228560

View Online

Abstract

Obstruction-induced acute pancreatitis in rats is associated with increased plasma cholecystokinin (CCK) levels. Duodenal replacement of bile reduces severity of pancreatitis and limits CCK increase. We investigated the role of CCK in the pathogenesis of obstruction-induced acute pancreatitis by pretreating rats with the somatostatin analog octreotide and the CCK antagonist L-364,718. Octreotide inhibits duodenal CCK release, and L-364,718 competitively blocks CCK receptors. We studied 31 rats after (1) sham operation (n = 7), (2) bile and pancreatic duct obstruction (BPDO) (n = 12), (3) BPDO plus octreotide (20 micrograms/kg IP and then 5 micrograms/kg/hr IV) (n = 6), and (4) BPDO plus L-364,718 (1 mg/kg IP and then 0.25 mg/kg/hr IV) (n = 6). Rats were killed after 18 hours. Pancreas weight, acute pancreatitis histology score, and plasma amylase and CCK levels were determined. Octreotide and L-364,718 limited the increase in pancreas weight. Octreotide also limited the rise in plasma CCK levels. These findings suggest that CCK may play a role in the pathogenesis of obstruction-induced acute pancreatitis.
Edema Acute Disease Benzodiazepinones - pharmacology Pancreatic Ducts Pancreas - drug effects Pancreas - pathology Rats Male Cholecystokinin - antagonists & inhibitors Devazepide Pancreatitis - drug therapy Octreotide - therapeutic use Octreotide - pharmacology Rats, Sprague-Dawley Animals Analysis of Variance Bile Ducts Pancreatitis - pathology Benzodiazepinones - therapeutic use

Details

Metrics

Logo image